231 related articles for article (PubMed ID: 31987984)
1. Current trends in theranostics for rheumatoid arthritis.
Madav Y; Barve K; Prabhakar B
Eur J Pharm Sci; 2020 Mar; 145():105240. PubMed ID: 31987984
[TBL] [Abstract][Full Text] [Related]
2. Nanomedicine - advantages for their use in rheumatoid arthritis theranostics.
Xiao S; Tang Y; Lv Z; Lin Y; Chen L
J Control Release; 2019 Dec; 316():302-316. PubMed ID: 31715278
[TBL] [Abstract][Full Text] [Related]
3. Ceria-based nanotheranostic agent for rheumatoid arthritis.
Kalashnikova I; Chung SJ; Nafiujjaman M; Hill ML; Siziba ME; Contag CH; Kim T
Theranostics; 2020; 10(26):11863-11880. PubMed ID: 33204316
[TBL] [Abstract][Full Text] [Related]
4. Bio-imaging and Photodynamic Therapy with Tetra Sulphonatophenyl Porphyrin (TSPP)-TiO2 Nanowhiskers: New Approaches in Rheumatoid Arthritis Theranostics.
Zhao C; Ur Rehman F; Yang Y; Li X; Zhang D; Jiang H; Selke M; Wang X; Liu C
Sci Rep; 2015 Jul; 5():11518. PubMed ID: 26153895
[TBL] [Abstract][Full Text] [Related]
5. Drug-loaded gold/iron/gold plasmonic nanoparticles for magnetic targeted chemo-photothermal treatment of rheumatoid arthritis.
Kim HJ; Lee SM; Park KH; Mun CH; Park YB; Yoo KH
Biomaterials; 2015 Aug; 61():95-102. PubMed ID: 26001074
[TBL] [Abstract][Full Text] [Related]
6. Solid Lipid Nanoparticles: A Potential Multifunctional Approach towards Rheumatoid Arthritis Theranostics.
Albuquerque J; Moura CC; Sarmento B; Reis S
Molecules; 2015 Jun; 20(6):11103-18. PubMed ID: 26087258
[TBL] [Abstract][Full Text] [Related]
7. Topical nanocarriers for management of Rheumatoid Arthritis: A review.
Anita C; Munira M; Mural Q; Shaily L
Biomed Pharmacother; 2021 Sep; 141():111880. PubMed ID: 34328101
[TBL] [Abstract][Full Text] [Related]
8. Recent Advances in Nanotheranostics for Treat-to-Target of Rheumatoid Arthritis.
Wang S; Lv J; Meng S; Tang J; Nie L
Adv Healthc Mater; 2020 Mar; 9(6):e1901541. PubMed ID: 32031759
[TBL] [Abstract][Full Text] [Related]
9. Nanomedicine: an emerging era of theranostics and therapeutics for rheumatoid arthritis.
Qamar N; Arif A; Bhatti A; John P
Rheumatology (Oxford); 2019 Oct; 58(10):1715-1721. PubMed ID: 31377812
[TBL] [Abstract][Full Text] [Related]
10. Nanotherapeutics relieve rheumatoid arthritis.
Yang M; Feng X; Ding J; Chang F; Chen X
J Control Release; 2017 Apr; 252():108-124. PubMed ID: 28257989
[TBL] [Abstract][Full Text] [Related]
11. Advances in Functionalized Mesoporous Silica Nanoparticles for Tumor Targeted Drug Delivery and Theranostics.
Zhang W; Liu M; Liu A; Zhai G
Curr Pharm Des; 2017; 23(23):3367-3382. PubMed ID: 27784244
[TBL] [Abstract][Full Text] [Related]
12. Multifunctional Janus Nanoplatform for Efficiently Synergistic Theranostics of Rheumatoid Arthritis.
Liu Y; Chen L; Chen Z; Liu M; Li X; Kou Y; Hou M; Wang H; Li X; Tian B; Dong J
ACS Nano; 2023 May; 17(9):8167-8182. PubMed ID: 37083341
[TBL] [Abstract][Full Text] [Related]
13. Dextran sulfate nanoparticles as a theranostic nanomedicine for rheumatoid arthritis.
Heo R; You DG; Um W; Choi KY; Jeon S; Park JS; Choi Y; Kwon S; Kim K; Kwon IC; Jo DG; Kang YM; Park JH
Biomaterials; 2017 Jul; 131():15-26. PubMed ID: 28371624
[TBL] [Abstract][Full Text] [Related]
14. Triple Hit with Drug Carriers: pH- and Temperature-Responsive Theranostics for Multimodal Chemo- and Photothermal Therapy and Diagnostic Applications.
Baek S; Singh RK; Kim TH; Seo JW; Shin US; Chrzanowski W; Kim HW
ACS Appl Mater Interfaces; 2016 Apr; 8(14):8967-79. PubMed ID: 26926826
[TBL] [Abstract][Full Text] [Related]
15. Liposome-Based Nanomedicine Therapeutics for Rheumatoid Arthritis.
Rahman M; Beg S; Anwar F; Kumar V; Ubale R; Addo RT; Ali R; Akhter S
Crit Rev Ther Drug Carrier Syst; 2017; 34(4):283-316. PubMed ID: 29199587
[TBL] [Abstract][Full Text] [Related]
16. Nanomedicines for improved targetability to inflamed synovium for treatment of rheumatoid arthritis: Multi-functionalization as an emerging strategy to optimize therapeutic efficacy.
Fang G; Zhang Q; Pang Y; Thu HE; Hussain Z
J Control Release; 2019 Jun; 303():181-208. PubMed ID: 31015032
[TBL] [Abstract][Full Text] [Related]
17. Lipid-based Vesicular Nanocargoes as Nanotherapeutic Targets for the Effective Management of Rheumatoid Arthritis.
Rahman M; Beg S; Sharma G; Saini S; Rub RA; Aneja P; Anwar F; Alam MA; Kumar V
Recent Pat Antiinfect Drug Discov; 2016; 11(1):3-15. PubMed ID: 27193030
[TBL] [Abstract][Full Text] [Related]
18. The axis of thrombospondin-1, transforming growth factor beta and connective tissue growth factor: an emerging therapeutic target in rheumatoid arthritis.
Rico MC; Rough JJ; Del Carpio-Cano FE; Kunapuli SP; DeLa Cadena RA
Curr Vasc Pharmacol; 2010 May; 8(3):338-43. PubMed ID: 19485899
[TBL] [Abstract][Full Text] [Related]
19. Current Developments in Therapeutic Drug Targeting for the Management of Rheumatoid Arthritis: An Emerging Paradigm.
Pai DR; Venkatesh MP; Kumar TMP
Crit Rev Ther Drug Carrier Syst; 2019; 36(6):485-536. PubMed ID: 32421953
[TBL] [Abstract][Full Text] [Related]
20. Magnetic nanoparticles: A new diagnostic and treatment platform for rheumatoid arthritis.
Liu Y; Cao F; Sun B; Bellanti JA; Zheng SG
J Leukoc Biol; 2021 Feb; 109(2):415-424. PubMed ID: 32967052
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
